Emergingby GlyphLoyal's large-dog lifespan drug LOY-003 earns FDA RXE
LOY-003 became Loyal's third program to earn Reasonable Expectation of Effectiveness from the FDA.
loyal.com
Longevity biotech
Pilotmomentum 433,519 papers a year (+32%)$1.0B raised in 12 months22 companies
Drugs and therapies that target the biology of aging itself to delay or reverse age-related decline and disease.
Why pilot: Life Biosciences dosed the first patient with ER-100, a partial epigenetic reprogramming therapy, in a Phase 1 trial. Jun 9, 2026
Dots under a month: dated events tracked here that month.
Events
All 26 eventsRentosertib trial data read out on six proteomic aging clocks
Nature Biotechnology reported that six clocks indicated reduced predicted biological age in treated IPF patients.
doi.org
XPRIZE Healthspan advances 20 finalist teams
Ten of the finalists received $1 million milestone awards in the $101 million competition.
xprize.org
First patient dosed with partial reprogramming therapy ER-100
Life Biosciences dosed the first participant in its Phase 1 trial of the OSK-based therapy.
lifebiosciences.com
Calico and Nexo Therapeutics sign small molecule discovery deal
The companies will jointly pursue Calico-nominated targets for age-related diseases.
calicolabs.com
Funding
NewLimit
Led by Founders Fund
$435MSource ↗
Retro Biosciences
Led by 4P Capital
Amount not disclosed; $1.8B pre-money valuationSource ↗
Life Biosciences
$80MSource ↗
Loyal
Led by age1, The Longevity Fund
$100MSource ↗
BioAge Labs
$115MSource ↗
Insilico Medicine
$293MSource ↗
NewLimit
$45MSource ↗
NewLimit
Led by Kleiner Perkins
$130MSource ↗
Shift Bioscience
Led by BGF
$16MSource ↗
BioAge Labs
$198MSource ↗
Loyal
Led by Bain Capital Ventures
$45MSource ↗
Companies
All 22 companiesLoyal
Veterinary drug company developing FDA-approved lifespan extension drugs for dogs.
loyal.com
Insilico Medicine
Generative AI drug discovery company that tests candidates such as rentosertib against aging clocks.
insilico.com
Life Biosciences
Develops partial epigenetic reprogramming therapies using OSK factors, led by ER-100 for optic neuropathies.
lifebiosciences.com
Calico Life Sciences
Alphabet-founded company researching the biology of aging and developing drugs for age-related diseases.
calicolabs.com
Nexo Therapeutics
Covalent small molecule discovery company working with Calico on targets for age-related diseases.
nexotx.com
BioAge Labs
Uses human aging biology to develop cardiometabolic drugs, including the NLRP3 inhibitor BGE-102.
bioagelabs.com
Researchers and labs
All 65 researchers and labsDae Sub Song
Publishes on Longevity biotech at Korea Disease Control and Prevention Agency: 39 papers in 2 years.
Sun Ha Jee
Publishes on Longevity biotech at Yonsei University: 39 papers in 2 years.
Su Hyun Lee
Publishes on Longevity biotech at Yonsei University: 39 papers in 2 years.
Kyoungho Lee
Publishes on Longevity biotech at Korea Institute of Energy Research: 39 papers in 2 years.
Altos Labs Institutes of Science
Company research institutes studying the biology of cell rejuvenation to reverse disease.
Babraham Institute Epigenetics programme
Epigenetics research within an institute whose research theme includes healthy ageing.
Most cited papers
All 35 papersPhase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease
Nobukatsu Sawamoto, Daisuke Doi, Etsuro Nakanishi et al. · Nature
Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update
Agnete Kirkeby, Heather Main, Melissa Carpenter · Cell stem cell
Senescence as a therapeutic target in cancer and age-related diseases
Domhnall McHugh, Imanol Durán, Jesús Gil · Nature Reviews Drug Discovery
The role of p21 in cellular senescence and aging-related diseases
Jiayu Yan, Siyi Chen, Zimei Yi et al. · Molecules and Cells
Spatial transcriptomic landscape unveils immunoglobin-associated senescence as a hallmark of aging
Shuai Ma, Zhejun Ji, Bin Zhang et al. · Cell
Patents
Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitor
Buck Institute for Research on Aging
Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
Unity Biotechnology Inc
Methods of treating retinal vasculopathies
Unity Biotechnology Inc
About longevity biotech here
- Sub-areas
- Partial epigenetic reprogrammingSenolytics and senescenceAutophagy and metabolic agingAging clocks and biomarkersAI-driven aging drug discoveryCell therapy and iPSC rejuvenationVeterinary longevity drugs
- Stage evidence
- Pilot, Jun 9, 2026: Life Biosciences dosed the first patient with ER-100, a partial epigenetic reprogramming therapy, in a Phase 1 trial. lifebiosciences.com
- Momentum
- 43 of 100: the mean of its ranks among the tracked fields for paper growth (56), funding in 12 months (38) and events in 90 days (34). Method
- Papers
- 3,519 in the 12 months ending two months ago, +32% against the 12 before (OpenAlex topics, journal and conference papers).
- Tracked here since
- Sep 25, 2026
- Weekly snapshots
- 5 weeks stored; latest Nov 2, 2026. JSON
Changes to this field
Longevity biotech
Tracked from here on: Drugs and therapies that target the biology of aging itself to delay or reverse age-related decline and disease.